Image may be NSFW.
Clik here to view.DRUG REGULATORY AFFAIRS INTERNATIONAL
Image may be NSFW.
Clik here to view.
Approximately two years ago the EMA published a draft guideline on process validation for the manufacture of biotech products. Now the final guideline has been published under the title “Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission“.
READ
Approximately two years ago the EMA published a draft guideline on process validation for the manufacture of biotech products. Now the final guideline has been published under the title “Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission”.
The scope of the guideline is to provide guidance on the data to be included in a regulatory submission to demonstrate that the active substance manufacturing process is in a validated state. The guideline focuses on recombinant proteins and polypeptides, their derivates, and products of which they are components (e.g…
View original post 300 more words
Filed under: Uncategorized Image may be NSFW.
Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.

Clik here to view.
